A5023100165- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Health and Medical Studies
- Autoimmune Bullous Skin Diseases
- Food Allergy and Anaphylaxis Research
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders Research
- Complementary and Alternative Medicine Studies
- Medicine and Dermatology Studies History
- Pharmaceutical studies and practices
- Public Administration and Political Analysis
- Urticaria and Related Conditions
- Contact Dermatitis and Allergies
- Cutaneous lymphoproliferative disorders research
- Skin Protection and Aging
- Cutaneous Melanoma Detection and Management
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Immunodeficiency and Autoimmune Disorders
- Medical History and Research
- COVID-19 Clinical Research Studies
- Clinical practice guidelines implementation
- Long-Term Effects of COVID-19
University Medical Center Hamburg-Eppendorf
2023
Praxis
2014-2023
Universitätsmedizin Greifswald
2023
University Hospital Münster
2023
Focus (Germany)
2023
Universität Hamburg
2023
Behörde für Gesundheit und Verbraucherschutz
2021
Berufsverband Niedergelassener Gynäkologischer Onkologen
2018
Bundeswehrzentralkrankenhaus Koblenz
2001
The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. is based on a systematic literature review completed December 1, 2016, and formal consensus approval process. first section this short version covers systemic options considered relevant by expert panel approved in Germany at time conference (acitretin, adalimumab, apremilast, cyclosporine, etanercept, fumaric acid esters, infliximab, methotrexate, secukinumab ustekinumab). Detailed information...
Summary Background The German psoriasis registry PsoBest records the long‐term efficacy, safety, patient benefit and treatment regimens of psoriasis. Patients methods with moderate or severe are included in when a conventional systemic agent biologic is started for first time. Observation time five years. Standardized physician case report forms obtained every three to six months. Baseline data patients by 31 December 2012 presented compared national health care study PsoHealth 2007 (n =...
Though patient needs are key drivers of treatment decisions, they rarely systematically investigated in routine care.This study aimed at analysing and expectations from the perspective German Swiss psoriasis registries PsoBest Dermatology Network Targeted Therapies (SDNTT) with respect to choice, age gender.The observe patients recruited first-time use systemic drugs. Within 10 years, clinical [Psoriasis Area Severity Index (PASI), Body Surface (BSA)] patient-reported outcomes documented,...
For the chapters 1 (Notes on use/Disclaimer), 3 (Funding), 4 (Scope and purpose of this guideline), 5 (Population health questions covered by guideline) 6 (Targeted users see long version guideline. All documents are available in an up-to-date following website: https://debm.charite.de/ Although it has its drawbacks, most established parameter to measure severity skin symptoms psoriasis is Psoriasis Area Severity Index (PASI), which was first introduced 1978 as outcome a retinoid trial [1]....
Summary This S3 guideline was created based on the European guideline, with special consideration of medical conditions in German‐speaking region and incorporating additions from previous German‐language version. The interdisciplinary commission consisted representatives German Dermatological Society, Professional Association Dermatologists, Austrian Society Dermatology Venereology, Swiss for Allergology Clinical Immunology, Pediatric Adolescent Medicine, Pediatricians Environmental...
Zusammenfassung Die deutsche Psoriasis‐Leitlinie zur Behandlung der Psoriasis vulgaris wurde unter Verwendung GRADE‐Methodik aktualisiert. Leitlinie aufbauend auf einer systematischen Literaturrecherche (letzte Update‐Recherche am 01.12.2016) entwickelt und in einem formalen Konsensus‐ Freigabeverfahren verabschiedet. Der erste Teil dieser Kurzfassung stellt die Empfehlungen zu den von Expertengruppe als relevant befundenen zum Zeitpunkt Konsensuskonferenz zugelassenen Therapien dar...
Psoriasis is associated with an increased rate of comorbidities, whose early detection has been adopted into the national healthcare goals. To date, agreed recommendations on in context routine dermatological care are missing. The objective this study was interdisciplinary development screening algorithms.The consensus paper based a three-step process. First, National Conference Healthcare Psoriasis, convening behalf German Society Dermatology (DDG) and Professional Association...
TREATgermany is an investigator-initiated prospective disease registry. It investigates physician- and patient-reported severity (Eczema Area Severity Index (EASI), objective Scoring Atopic Dermatitis (oSCORAD), Investigator Global Assessment, Patient-Oriented Eczema Measure (POEM), Patient Assessment (PGA)), symptoms (itch, sleep loss, depressive symptoms), therapy courses dermatological quality of life (DLQI) in moderate-to-severe atopic dermatitis with SCORAD > 20. 1,134 patients (mean...
The Atopic Dermatitis (AD) TREATgermany registry was initiated by the German Society for Dermatology (DDG) in 2011 to evaluate 'real-life' situation of health care patients with AD.Interim data analysis on baseline characteristics as well current and prescribed systemic treatments patients.Patients (≥18 years) moderate-to-severe AD [objective (o)SCORAD > 20], or previous anti-inflammatory treatment within 24 months, were included are followed up over at least months. To assess clinical...
Summary The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. is based on a systematic literature review completed December 1, 2016, and formal consensus approval process. second part this short version covers following special patient populations situations: tuberculosis screening before during treatment, choice individuals wishing to have children, as well pregnancy breast‐feeding, patients with joint involvement vaccinations. In addition,...
Teledermatologische Anwendungen werden im deutschen Versorgungssystem in den nächsten Jahren erheblich an Bedeutung gewinnen. Das vorliegende Empfehlungspapier wurde als Expertenkonsens auf der Basis einer qualifizierten Literaturrecherche und eines strukturierten Entscheidungsprozesses Autorengruppe entwickelt. ZIELSETZUNG: a) die IST-Analyse zum Einsatz Telemedizin Dermatologie, b) Bewertung Evidenz ihres Nutzens ihrer Sicherheit und, c) Entwicklung von Verfahrensstandards für ärztliche...
Für die Kapitel 1 (Hinweise zur Anwendung der Leitlinie/Haftungsausschluss), 3 (Finanzierung), 4 (Gegenstand und Ziele Leitlinie), 5 (Patientenzielgruppe zu behandelnde Fragestellungen) 6 (Zielgruppe dieser Leitlinie) siehe Langfassung Leitlinie. Die in diesem Werk verwandten Personen- Berufsbezeichnungen sind, auch wenn sie nur einer Form auftreten, gleichwertig auf beide Geschlechter bezogen. Alle Dokumente finden Sie aktueller Version folgender Seite: https://debm.charite.de/ Trotz...
For chapters 1 (Notes on use/Disclaimer), 3 (Funding), 4 (Scope and purpose of this guideline), 5 (Population health questions covered by the guideline) 6 (Targeted users see long version guideline. All documents are available in an up-to-date following website: https://debm.charite.de Guideline text recommendations This chapter is based related previous versions guideline [1, 2]. An existing systematic review meta-analysis was updated, details which can be found Development Report....
Summary The present S3 guideline was created based on the European English‐language guideline, with special consideration given to medical conditions in German‐speaking region, and additions from previous German‐language version, accordance criteria of AWMF. This second part addresses systemic therapy atopic dermatitis (AD). It covers topics such as indication for children, adolescents, adult patients AD. Furthermore, it all medications approved AD, biologics dupilumab tralokinumab, Janus...
The CARPE registry was set up in 2009 to prospectively investigate the management of patients with chronic hand eczema (CHE).To report comprehensive follow-up data from registry.We investigated sociodemographic and clinical characteristics, provision medical care, physician-assessed outcomes, patient-reported outcomes (PROs). Data were collected between 2016, 5 years follow-up, are reported descriptively.Overall, 1281 included (53.7% female). Mean age 47.0 years. Of patients, 793 231...
The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology rheumatology as well policymakers insurance funds. They were developed by dermatologists collaboration with rheumatologists using a formal consensus process (S2k). highlight topics such disease severity, quality life, treatment goals problems associated off-label drug therapy children. Trigger factors diagnostic aspects discussed. primary focus is on...
Summary The present guidelines are aimed at residents and board‐certified physicians in the fields of dermatology, pediatrics, pediatric dermatology rheumatology as well policymakers insurance funds. They were developed by dermatologists collaboration with rheumatologists using a formal consensus process (S2k). highlight topics such disease severity, quality life, treatment goals problems associated off‐label drug therapy children. Trigger factors diagnostic aspects discussed. primary focus...
Die topische Behandlung der Psoriasis und ihrer Sonderformen hat einen hohen Stellenwert im Praxisalltag. Sie ist Therapiestandard bei leichter wird unterstützend auch mittelschwerer bis schwerer eingesetzt. Bei Optimierung spielt neben den geeigneten Wirkstoffen die Wahl Galenik eine entscheidende Rolle. Weiterentwicklungen in diesem Bereich wurden 2017 publizierten Aktualisierung S3-Leitlinie nicht berücksichtigt. Der vorliegende Behandlungspfad wurde Rahmen PsoNet-Sprecherkonferenz...
Randomized controlled trials of secukinumab have shown sustained efficacy and a favourable safety profile in multiple manifestations psoriatic disease.To assess the long-term, real-world retention, effectiveness routine clinical practice for treatment moderate-to-severe plaque-type psoriasis (PsO).SERENA (CAIN457A3403) is large, ongoing, longitudinal, observational study conducted at 438 sites 19 countries an expected duration up to 5 years adult patients with PsO, arthritis ankylosing...